Patents Examined by Sergio Coffa
  • Patent number: 10479854
    Abstract: A peptide-polymer conjugate is provided for use in treating malaria infections, and in particular terminal or drug resistant malaria infections. The conjugate is formed from a polymer to which a peptide having activity against a malaria parasite is co-valently attached. The peptide is a cyclic decapeptide from the closely-related group of tyrocidines, tryptocidines, phenycidines and gramicidin S, and the polymer is a hydrophilic and biocompatible polymer with a terminal thiol, such as poly(N-vinylpyrrolidone) (PVP). The polymer chains can be decorated with a hydrophilic targeting ligand that specifically targets an epitope on red blood cells, and in particular red blood cells infected with a plasmodial parasite. A method for synthesising the peptide-polymer conjugate is also provided.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: November 19, 2019
    Assignee: Stellenbosch University
    Inventors: Lubertus Klumperman, Paul William Reader, Marina Rautenbach
  • Patent number: 10464977
    Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: November 5, 2019
    Assignees: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
  • Patent number: 10456443
    Abstract: Improved calcineurin inhibitors and methods of using these improved calcineurin inhibitors to inhibit calcineurin-NFAT signaling in cells and in subjects are disclosed.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: October 29, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Dehua Pei, Ziqing Qian, John W Christman, Manjula Karpurapu
  • Patent number: 10441664
    Abstract: The disclosure describes collagen constructs comprising antimicrobial agents and related methods.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: October 15, 2019
    Assignee: MiMedx Group, Inc.
    Inventor: Thomas J. Koob
  • Patent number: 10441560
    Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 15, 2019
    Assignee: Mochida Pharmaceutical Co., LTD.
    Inventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
  • Patent number: 10434149
    Abstract: A method of promoting hemostasis in a subject in need thereof includes administering to the subject a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, wherein the peptides include a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and an active platelet GPM-Ma-binding peptides (GBPs).
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: October 8, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Anirban Sen Gupta, Christa Pawlowski
  • Patent number: 10433576
    Abstract: A method of alleviating symptoms of, or treating, pancreatic beta-cell damage in a subject includes a step of identifying a subject having pancreatic beta-cell damage. Multiple cycles of a diet protocol are administered to the subject. The diet protocol includes administering of a fasting mimicking diet and a re-feeding diet where the fasting mimicking diet is provided for a first time period and the re-feeding diet is provided for a second time period.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: October 8, 2019
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Chia-Wei Cheng
  • Patent number: 10429129
    Abstract: Methods for preparing dried pellets of biological materials are described. The pellets can have a substantially spherical shape and are prepared by freezing droplets of a liquid composition of a desired biological material on a solid surface followed by microwave vacuum drying the frozen droplets. These methods are useful for preparing dried pellets having a high concentration of a desired biological material, in particular a therapeutic protein or vaccine, and which have a faster reconstitution time than lyophilized powder cakes prepared in vials.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: October 1, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Jessica Sinacola, Rebecca Lizzano
  • Patent number: 10426820
    Abstract: A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 1, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Anirban Sen Gupta, Christa Pawloski
  • Patent number: 10414808
    Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, methods of making and using the foregoing, and methods of alleviating pain with peptide inhibitors of Nav1.7.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 17, 2019
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: William Eckert, Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
  • Patent number: 10416170
    Abstract: The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 17, 2019
    Assignee: OXPROTECT GMBH
    Inventors: Beate Kehrel, Martin Brodde
  • Patent number: 10406200
    Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 10, 2019
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Roland R. Arnold, David C. Henke
  • Patent number: 10406204
    Abstract: The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 10, 2019
    Assignees: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, INTELLIGENT SYNTHETIC BIOLOGY CENTER
    Inventors: Sun-Chang Kim, Ju Ri Shin, Ki Jung Lim, Da Jung Kim, Young Woong Lee, Su A Jang, Bong Hyun Sung
  • Patent number: 10400018
    Abstract: Isolated tau peptides, and compositions comprising the peptides are disclosed. Further provided are antibodies specific for an isolated tau peptide. Methods of using the isolated tau peptide in diagnostic and treatment including using a pharmaceutical composition comprising the isolated tau peptide for stimulating an immune response in an individual to a tau peptide, and methods of using antibodies in detection, diagnosis, and treatment of disorders including a tauopathy are further provided.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: September 3, 2019
    Assignee: iPierian, Inc.
    Inventors: Irene Griswold-Prenner, Graham Parry, Tony SangYoung Byun
  • Patent number: 10363282
    Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 30, 2019
    Assignees: Board of Regents of The University of Nebraska, San Diego State University Research Foundation
    Inventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
  • Patent number: 10357539
    Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of Princeton University, Wisconsin Alumni Research Foundation
    Inventors: Yibin Kang, Yongna Xing, Liling Wan, Feng Guo
  • Patent number: 10351599
    Abstract: Described herein are anti-microbial peptides having enhanced activity and transport.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 16, 2019
    Assignee: Tensive Controls, Inc.
    Inventor: Kenneth Allen Gruber
  • Patent number: 10351608
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 16, 2019
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Patent number: 10351601
    Abstract: The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptides. Compounds of the invention can be used to treat a variety of clinical conditions, including but not limited to, cancers, pulmonary fibrosis, HIV infection, rheumatoid arthritis, and other immune disorders. In addition, compounds of the invention can also be used in stem cell therapy.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: July 16, 2019
    Assignee: Mainline Biosciences
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 10322188
    Abstract: This invention is about a cell-penetrating drug carrier and the application thereof. The mentioned cell-penetrating drug carrier can approach the target cell through using a proper recognizable sequence, so that the cell-penetrating drug carrier can be used to specifically delivery wanted drug to target cell. Through carrying wanted drug into the cytoplasm of the target cell by cell-penetrating peptide, the drug accumulation volume in the target cell can be efficiently increased. Preferably, through using proper bioinert polymer, the cell-penetrating peptide and the recognizable sequence can be kept from been digested before approaching the target cell.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 18, 2019
    Assignee: NATIONAL CENTRAL UNIVERSITY
    Inventors: Ruoh-Chyu Ruaan, Ching-Wei Tsai, Chuan-Hui Lu, Yung Chang